Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Medicare Coverage Advisory Committee's Diagnostic Imaging Panel will hold a Jan. 10 meeting to discuss whether and when it is scientifically justified to use fluoro-D-glucose positron emission tomography or other neuro-imaging devices for the diagnosis and patient management of Alzheimer's disease, a Nov. 23 Federal Register notice announces. The meeting will focus on asymptomatic patients who are at high risk of AD due to positive family history, patients with mild cognitive impairment or similar syndrome and patients with dementia. The deadline for presentations and comments is Dec. 27...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts